<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2093">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133921</url>
  </required_header>
  <id_info>
    <org_study_id>CAGE-FREE registry</org_study_id>
    <nct_id>NCT05133921</nct_id>
  </id_info>
  <brief_title>The Clinical Efficacy and Safety of Drug-coated Balloon</brief_title>
  <official_title>The Clinical Efficacy and Safety of Drug-coated Balloon in Coronary Lesions: a Real-World, All-Comers ,Single-center, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty&#xD;
      procedurally, but there is an anti-proliferative medication paclitaxel coated on the balloon.&#xD;
      Treating in-stent restenosis (ISR) with the DCB has the theoretical advantage of avoiding&#xD;
      multiple stent layers and respecting the vessel anatomy. DCB has shown promising results for&#xD;
      the treatment of ISR. Currently, DCB has a Class I indication to treat ISR recommended by&#xD;
      European Society of Cardiology (ESC) guidelines. In addition, some interventional&#xD;
      cardiologist has also applied DCB in de novo lesions in their clinical practice.&#xD;
&#xD;
      Although some small sample size RCTs and observational studies have suggested that the&#xD;
      clinical prognosis of DCB in primary large vessels is non-inferior to drug-eluting stent&#xD;
      (DES), there is no large-scale RCT or cohort studies to compare the clinical effects of DCB&#xD;
      and DES.&#xD;
&#xD;
      Despite several theoretical benefits of DCB, the procedural-related complications cannot be&#xD;
      entirely prevented, such as acute elastic retraction and severe dissection, which would&#xD;
      affect coronary blood flow or lead to acute vascular occlusion.&#xD;
&#xD;
      Some studies have suggested that optimization of the procedural technique can reduce the&#xD;
      occurrence of complications and target lesion failure in the long-term. Proposed criteria&#xD;
      include adapting cutting or scoring balloon for pre-dilatation, residual stenosis&lt;30%&#xD;
      post-DCB, maintaining TIMI flow=3, DCB dilation time&lt;60s, and appropriate balloon to vessel&#xD;
      ratio&gt; 0.91. However, such proposed technique and criteria have not been evaluated in the&#xD;
      real-world clinical practice.&#xD;
&#xD;
      This current study is designed to investigate the efficacy and safety of DCB in the real&#xD;
      world and exploring the optimal procedural configurations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2015</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Patient-oriented Composite Endpoint (PoCE)</measure>
    <time_frame>24 months</time_frame>
    <description>POCE is a composite clinical endpoint of all-cause death, any stroke, any non-fatal myocardial infarction (MI), any revascularization</description>
  </primary_outcome>
  <other_outcome>
    <measure>POCE</measure>
    <time_frame>1 or 12 months</time_frame>
    <description>POCE is a composite clinical endpoint of all-cause death, any stroke, non-fatal myocardial infarction (MI), any revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause death</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-fatal myocardial infarction (MI)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Any stroke</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Any revascularization</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of PoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>DoCE is a composite clinical endpoint of cardiac death, target vessel myocardial infraction (TV-MI), and Clinically individual target lesion revascularization (CI-TLR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Target vessel myocardial infraction (TV-MI)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically individual target lesion revascularization (CI-TLR)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of DoCE</description>
  </other_outcome>
  <other_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Target vessel failure is defined as cardiovascular death, target vessel myocardial infraction (TV-MI), and clinically-indicated target vessel revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-indicated target vessel revascularization</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of TVF</description>
  </other_outcome>
  <other_outcome>
    <measure>BARC type 3 or 5 bleeding events</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Bleeding events type 3 or 5 defined by BARC (Bleeding Academic Research Consortium) criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Net adverse clinical events (NACE)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>NACE is a composite clinical endpoint of all-cause death, any stroke, any any non-fatal myocardial infarction ( MI) any revascularization and BARC type 3 or 5 bleeding events</description>
  </other_outcome>
  <other_outcome>
    <measure>Vessel-oriented Composite Endpoint (VOCE)</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>VOCE is a composite clinical endpoint of Vessel-related cardiovascular Death, Target-vessel related MI, Clinically-oriented Target vessel revascularization</description>
  </other_outcome>
  <other_outcome>
    <measure>Vessel-related cardiovascular Death</measure>
    <time_frame>1, 12, or 24 months</time_frame>
    <description>Rates of individual components of VOCE</description>
  </other_outcome>
  <enrollment type="Actual">2487</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Angioplasty, Balloon</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who received PCI with one or more drug-coated balloons (DCB) in the Xijing&#xD;
        hospital of the Air Force Medical University from December 1, 2015 to December 1, 2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who received PCI with one or more drug-coated balloons (DCB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Currently participating in another trial or participants unable to comply to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Tao, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao Gao, MD, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ling Tao</name>
      <address>
        <city>Xi'an</city>
        <state>Shannxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>LingTao</investigator_full_name>
    <investigator_title>Professor in Cardiology, Director of the department of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Drug-coated balloons</keyword>
  <keyword>De-novo</keyword>
  <keyword>All-comers</keyword>
  <keyword>In-stent stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

